Acoramidis Clinical Trials (2026): 10 Studies for Amyloidosis & Cardiomyopathies
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Acoramidis clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Amyloidosis & Cardiomyopathies) and 4,140 total planned enrollment. 5 Phase 3 Acoramidis trials, 2 Phase 4 are listed. 5 Acoramidis clinical trials are actively recruiting at 39 U.S. sites across 23 states. Most recent activity: NCT07116473 (Dec 2037).
Where to Participate: All Acoramidis Trial Sites in the U.S. (39 sites across 23 states)
Every actively recruiting Acoramidistrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California, San Diego (UCSD) - Medical Center | La Jolla92037 | NCT06563895 | Map |
| CA | University of California, Los Angeles (UCLA) - David Geffen School of Medicine | Los Angeles90095 | NCT06563895 | Map |
| CA | University of California, San Francisco (UCSF) | San Francisco94143 | NCT06563895 | Map |
| CA | Stanford University | Stanford94305 | NCT06563895 | Map |
| CO | University of Colorado Anschutz | Aurora80045 | NCT06563895 | Map |
| CT | Yale University School of Medicine - Section of Cardiology | New Haven06519 | NCT06563895 | Map |
| DC | MedStar Washington Hospital Center - MedStar Heart and Vascular Institute | Washington D.C.20010 | NCT06563895 | Map |
| FL | Mayo Clinic - Jacksonville | Jacksonville32224 | NCT06563895 | Map |
| FL | Cleveland Clinic Florida | Weston33331 | NCT06563895 | Map |
| GA | Emory University School of Medicine | Atlanta30322 | NCT06563895 | Map |
| IL | John H. Stroger, Jr. Hospital of Cook County | Chicago60612 | NCT06563895 | Map |
| IL | University of Chicago - Medical Center | Chicago60637 | NCT06563895 | Map |
| MD | Johns Hopkins University | Baltimore21287 | NCT06563895 | Map |
| MD | University of Maryland Medical Center | Baltimore21201 | NCT06563895 | Map |
| MA | Boston University (BU) School of Medicine | Boston02118 | NCT06563895 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT06563895 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06563895 | Map |
| MI | Henry Ford Health System | Detroit48202 | NCT06563895 | Map |
| MN | Mayo Clinic - Rochester | Rochester55905 | NCT06563895 | Map |
| MO | St. Luke's Hospital of Kansas City | Kansas City64111 | NCT06563895 | Map |
| MO | Washington University in St. Louis | St Louis63110 | NCT06563895 | Map |
| NJ | Rutgers-Robert Wood Johnson Medical School | New Brunswick08901 | NCT06563895 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT06563895 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT06563895 | Map |
| NY | New York University (NYU) School of Medicine - Langone Medical Center | New York10016 | NCT06563895 | Map |
| NY | Laurelton Heart Specialists | Rosedale11422 | NCT06563895 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06563895 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT06563895 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT06563895 | Map |
| PA | Penn Presbyterian Medical Center | Philadelphia19104 | NCT06563895 | Map |
| PA | University of Pittsburgh Medical Center, Presbyterian Hospital | Pittsburgh15213 | NCT06563895 | Map |
| SC | Medical University of South Carolina (MUSC) | Charleston29425 | NCT06563895 | Map |
| SC | Prisma Health Cancer Institute | Greenville89605 | NCT06563895 | Map |
| TX | National Neuromuscular Research Institute | Austin78759 | NCT06563895 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT06563895 | Map |
| UT | University of Utah | Salt Lake City84132 | NCT06563895 | Map |
| VA | INOVA Fairfax Hospital | Falls Church22042 | NCT06563895 | Map |
| VA | Virginia Commonwealth University | Richmond23219 | NCT06563895 | Map |
| WA | University of Washington Medical Center | Seattle98195 | NCT06563895 | Map |
Acoramidis clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|
| P1 | 2 | 2 | ||||
| P3 | 1 | 1 | 1 | 1 | 1 | 5 |
| P4 | 2 | 2 | ||||
| N/A | 1 | 1 |
Recruiting Acoramidis clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07116473 | ACT-EARLY OLETo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) | P3 | Amyloidosis in Transthyretin (TTR) | 250 | Nov 2025 |
| NCT06563895 | ACT-EARLYAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | P3 | Amyloidosis | 587 | May 2025 |
| NCT07235462 | ACO-REALA Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting | — | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 2,000 | Oct 2025 |
| NCT07306949 | ATTR-CMReal-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | P4 | Transthyretin-type Cardiac Amyloidosis | 200 | Oct 2025 |
| NCT07298044 | ACO-SWITCHA Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis | P4 | Transthyretin Amyloid Cardiomyopathy | 50 | Feb 2026 |
Acoramidis clinical trials by indication
Amyloidosis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06563895 | ACT-EARLY | P3 | recruiting | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant |
| NCT03860935 | ATTRibute-CM | P3 | completed | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy |
| NCT04769479 | — | P1 | completed | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects |
Transthyretin Amyloid Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07298044 | ACO-SWITCH | P4 | recruiting | A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis |
Amyloidosis in Transthyretin (TTR) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07116473 | ACT-EARLY OLE | P3 | not yet recruiting | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) |
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07235462 | ACO-REAL | N/A | recruiting | A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting |
Transthyretin-type Cardiac Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07306949 | ATTR-CM | P4 | recruiting | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers |
Amyloid Cardiomyopathy, Transthyretin-Related (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04988386 | AG10 | P3 | active not recruiting | Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants |
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04882735 | AG10 | P3 | withdrawn | Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04958135 | — | P1 | completed | Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants |
Acoramidis pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ATTR-CM | NCT07306949 | P4 | recruiting | Transthyretin-type Cardiac Amyloidosis | 200 | — |
| ACO-SWITCH | NCT07298044 | P4 | recruiting | Transthyretin Amyloid Cardiomyopathy | 50 | — |
| ACT-EARLY OLE | NCT07116473 | P3 | not yet recruiting | Amyloidosis in Transthyretin (TTR) | 250 | — |
| ACT-EARLY | NCT06563895 | P3 | recruiting | Amyloidosis | 587 | — |
| AG10 | NCT04988386 | P3 | active not recruiting | Amyloid Cardiomyopathy, Transthyretin-Related | 389 | PMID 41911489 |
| AG10 | NCT04882735 | P3 | withdrawn | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | 0 | — |
| ATTRibute-CM | NCT03860935 | P3 | completed | Amyloidosis | 632 | PMID 42110872 |
Terminated and withdrawn Acoramidis trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04882735withdrawnEfficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
All Acoramidis trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07116473 | ACT-EARLY OLE | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) | P3 | not yet recruiting | 250 | Eidos Therapeutics, a BridgeBio company | Nov 2025 |
| NCT06563895 | ACT-EARLY | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | P3 | recruiting | 587 | Eidos Therapeutics, a BridgeBio company | May 2025 |
| NCT07235462 | ACO-REAL | A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting | — | recruiting | 2,000 | Bayer | Oct 2025 |
| NCT04988386 | AG10 | Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants | P3 | active not recruiting | 389 | Eidos Therapeutics, a BridgeBio company | Oct 2021 |
| NCT07306949 | ATTR-CM | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | P4 | recruiting | 200 | Alexion Pharmaceuticals, Inc. | Oct 2025 |
| NCT07298044 | ACO-SWITCH | A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis | P4 | recruiting | 50 | Bayer | Feb 2026 |
| NCT04882735 | AG10 | Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) | P3 | withdrawn | 0 | Eidos Therapeutics, a BridgeBio company | Sep 2021 |
| NCT03860935 | ATTRibute-CM | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy | P3 | completed | 632 | Eidos Therapeutics, a BridgeBio company | Mar 2019 |
| NCT04769479 | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects | P1 | completed | 14 | Eidos Therapeutics, a BridgeBio company | Mar 2021 | |
| NCT04958135 | Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants | P1 | completed | 18 | Alexion Pharmaceuticals, Inc. | May 2021 |
Acoramidis clinical trials: frequently asked questions
- How many Acoramidis clinical trials are there?
- 10 Acoramidis clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 3 are marked completed.
- Are Acoramidis clinical trials recruiting in 2026?
- Yes — 4 Acoramidis trials are actively recruiting in 2026, with 39 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Acoramidis being studied for?
- Acoramidis is being studied for Amyloidosis, Cardiomyopathies, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Amyloid Cardiomyopathy, Transthyretin-Related and 12 more. The trials are grouped by indication on this page.
- What phase is Acoramidis in?
- Acoramidis clinical trials span 2 Phase 4, 5 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Acoramidis clinical trials?
- The lead sponsor across the most Acoramidis trials is Eidos Therapeutics, a BridgeBio company, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Acoramidisas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: